Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Inflaming the microenvironment of colorectal cancer to enable immunotherapy

Ziel

Microsatellite-stable colorectal cancer (MSS CRC) accounts for 85–90% of CRCs and remains largely resistant to immune checkpoint blockade (ICB), one of the most transformative advances in oncology. Consequently, the majority of patients with advanced CRC cannot benefit from immunotherapy, representing a major unmet clinical need. INFLAME-TME proposes a novel strategy to overcome this limitation by converting immunologically “cold” MSS tumors into ICB-responsive lesions through targeted induction of tumor-intrinsic immunogenic stress.
Building on discoveries from the ERC AdG PLASTICAN, we identified a previously unrecognized target that is responsible for mitotic spindle assembly while its downregulation causes chromosome missegregation, micronucleus formation, and activation of the cGAS/STING innate immune pathway. In preclinical models of MSS CRC, depletion induces strong CD8⁺ T cell infiltration and sensitizes tumors to ICB. To translate this discovery into a therapeutic strategy, we developed a targeted RNA-based approach aiming to impair tumor cell division while triggering innate immune activation within the tumor microenvironment. INFLAME-TME will assess the technical feasibility and translational potential of this strategy. Key objectives include validating mitotic disruption and cGAS/STING activation, evaluating ICB sensitization, and defining the intellectual property, regulatory, and commercialization paths for further development.
If successful, INFLAME-TME will establish a new paradigm in cancer immunotherapy where targeted RNA delivery induces tumor-intrinsic immunogenicity to overcome ICB resistance. Beyond CRC, this concept could open opportunities for RNA-based immunomodulatory therapies across diverse immunotherapy-resistant malignancies.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG
Netto-EU-Beitrag
€ 150 000,00
Adresse
PAUL EHRLICH STRASSE 42-44
60596 FRANKFURT
Deutschland
Region
Berlin Berlin Berlin
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)